# Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

> **NCT06016972** · PHASE2 · COMPLETED · sponsor: **Qlaris Bio, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Primary Open Angle Glaucoma (POAG)
- Primary Open Angle Glaucoma of Both Eyes
- Primary Open-Angle Glaucoma, Unspecified Eye
- Ocular Hypertension (OHT)

## Interventions

- **DRUG:** Experimental: QLS-111 ophthalmic solution, (0.015%)
- **DRUG:** Experimental: QLS-111 ophthalmic solution, (0.03%)
- **DRUG:** Experimental: QLS-111 ophthalmic solution, (0.075%)
- **OTHER:** QLS-111 ophthalmic vehicle solution

## Key facts

- **NCT ID:** NCT06016972
- **Lead sponsor:** Qlaris Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-05
- **Primary completion:** 2024-08-20
- **Final completion:** 2024-08-20
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016972, "Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06016972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*